Gene Sequencing, Genetics and Pharma Companies

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The deal is mostly back-loaded, with “double-digit million” dollars in upfront payment, research funding and milestone payments.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

MAY 26, 2023

The British company’s expanded facilities boasts of 11 suites, including two class B filling suites with class A filling cabinets, warehousing and quality control laboratory capability. One big pharma company has already given the seal of approval with a successful customer quality audit.

DNA

DNA Manufacturing Gene Gene Therapy

Clinical Research Informer

Takeda grows in gene therapies again with $2bn Code Bio deal

Touchlight boosts DNA manufacturing capacity with latest expansion

Webinars

Stay Connected